Lorlatinib is active in the treatment of CNS metastases for ALK-positive advanced LCNEC.The significantly improved PFS observed in this patient emphasizes the importance of lorlatinib as the first-line treatment for advanced LCNEC. Here, ALK is linked to large cell neuroendocrine carcinoma.